• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英格兰丙型肝炎的负担。

The burden of hepatitis C in England.

作者信息

Sweeting M J, De Angelis D, Brant L J, Harris H E, Mann A G, Ramsay M E

机构信息

MRC Biostatistics Unit, Institute of Public Health, Robinson Way, Cambridge, UK.

出版信息

J Viral Hepat. 2007 Aug;14(8):570-6. doi: 10.1111/j.1365-2893.2007.00851.x.

DOI:10.1111/j.1365-2893.2007.00851.x
PMID:17650291
Abstract

In England, a large number of individuals are infected with the hepatitis C virus (HCV) and may develop future liver complications, such as decompensated cirrhosis and hepatocellular carcinoma (HCC). Estimates of the magnitude of this future burden are required to plan healthcare resources. We have estimated past incidence of HCV infection in England and predict future burden of end-stage liver disease in the HCV-infected population. A model of the natural history of HCV as a series of disease stages was constructed. A back-calculation approach was performed, using the natural history model and data on annual HCC deaths in England from 1996 to 2004 with mention of HCV and hospital episode statistics for end-stage liver disease with HCV. The number of HCV-infected people living with compensated cirrhosis is predicted to rise from 3705 [95% credible interval (CrI): 2820-4975] in 2005 to 7550 (95% CrI: 5120-11,640) in 2015. The number of decompensated cirrhosis and/or HCC cases is also predicted to rise, to 2540 (95% CrI: 2035-3310) by 2015. HCV incidence increased during the 1980s, with an annual incidence of 12 650 (95% CrI: 6150-26,450) by 1989. HCV-related cirrhosis and deaths from HCC in England are likely to increase dramatically within the next decade. If patients are left undiagnosed and untreated, the future burden of the disease on healthcare resources will be substantial.

摘要

在英国,大量个体感染了丙型肝炎病毒(HCV),可能会在未来出现肝脏并发症,如失代偿性肝硬化和肝细胞癌(HCC)。为了规划医疗资源,需要对这一未来负担的规模进行估计。我们已经估算了英国过去HCV感染的发病率,并预测了HCV感染人群中终末期肝病的未来负担。构建了一个将HCV自然史描述为一系列疾病阶段的模型。采用了回溯计算方法,利用该自然史模型以及1996年至2004年英国年度HCC死亡数据(提及HCV)和HCV终末期肝病的医院就诊统计数据。预计2005年患有代偿性肝硬化的HCV感染者人数为3705人[95%可信区间(CrI):2820 - 4975],到2015年将增至7550人(95% CrI:5120 - 11,640)。失代偿性肝硬化和/或HCC病例数预计也会增加,到2015年将增至2540例(95% CrI:2035 - 3310)。20世纪80年代HCV发病率上升,到1989年年度发病率为12650例(95% CrI:6150 - 26,450)。未来十年内,英国与HCV相关的肝硬化和HCC死亡人数可能会大幅增加。如果患者未被诊断和治疗,该疾病对医疗资源造成的未来负担将是巨大的。

相似文献

1
The burden of hepatitis C in England.英格兰丙型肝炎的负担。
J Viral Hepat. 2007 Aug;14(8):570-6. doi: 10.1111/j.1365-2893.2007.00851.x.
2
Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection.重建与预测希腊丙型肝炎病毒疫情:尽管丙型肝炎病毒感染发病率下降,但肝硬化和肝细胞癌呈上升趋势。
J Viral Hepat. 2004 Jul;11(4):366-74. doi: 10.1111/j.1365-2893.2004.00517.x.
3
Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.与 HCV 单感染患者相比,合并感染人类免疫缺陷病毒/丙型肝炎病毒(HCV)的肝硬化患者发生肝细胞癌或终末期肝病的风险不再更高。
Hepatology. 2019 Sep;70(3):939-954. doi: 10.1002/hep.30400. Epub 2019 Mar 15.
4
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.模拟改善慢性丙型肝炎病毒感染的筛查和治疗对未来肝细胞癌发病率及肝脏相关死亡率的影响。
BMC Gastroenterol. 2014 Aug 7;14:137. doi: 10.1186/1471-230X-14-137.
5
Disease burden of chronic hepatitis C in Brazil.巴西慢性丙型肝炎的疾病负担。
Braz J Infect Dis. 2015 Jul-Aug;19(4):363-8. doi: 10.1016/j.bjid.2015.04.004. Epub 2015 Jun 4.
6
Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.需要增加摄取量和新疗法来避免英格兰丙型肝炎相关终末期肝病的上升:在不同情况下模拟治疗的预测影响。
J Hepatol. 2014 Sep;61(3):530-7. doi: 10.1016/j.jhep.2014.05.008. Epub 2014 May 10.
7
Data linkage to monitor hepatitis C-associated end-stage liver disease and hepatocellular carcinoma inpatient stays in England.利用数据链接监测英格兰丙型肝炎相关终末期肝病和肝细胞癌的住院情况。
J Viral Hepat. 2020 Jan;27(1):20-27. doi: 10.1111/jvh.13203. Epub 2019 Oct 3.
8
Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.注射吸毒者中的丙型肝炎病毒(HCV)疾病进展:一项系统评价和荟萃分析。
Int J Drug Policy. 2015 Oct;26(10):911-21. doi: 10.1016/j.drugpo.2015.07.004. Epub 2015 Jul 26.
9
Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.在澳大利亚新南威尔士州直接作用抗病毒治疗时代,丙型肝炎病毒相关肝病负担下降。
J Hepatol. 2019 Aug;71(2):281-288. doi: 10.1016/j.jhep.2019.04.014. Epub 2019 May 10.
10
Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.2001年澳大利亚丙型肝炎病毒发病率、流行率及长期后遗症建模
Int J Epidemiol. 2003 Oct;32(5):717-24. doi: 10.1093/ije/dyg101.

引用本文的文献

1
Machine Learning Model Validated to Predict Outcomes of Liver Transplantation Recipients with Hepatitis C: The Romanian National Transplant Agency Cohort Experience.机器学习模型验证用于预测丙型肝炎肝移植受者的结局:罗马尼亚国家移植机构队列经验。
Sensors (Basel). 2023 Feb 14;23(4):2149. doi: 10.3390/s23042149.
2
Estimation of COVID-19 Period Prevalence and the Undiagnosed Population in Canadian Provinces: Model-Based Analysis.基于模型的分析:估算加拿大各省 COVID-19 流行期患病率和未诊断人群。
JMIR Public Health Surveill. 2021 Sep 9;7(9):e26409. doi: 10.2196/26409.
3
Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update.
慢性丙型肝炎纤维化进展率的估计:系统评价和荟萃分析更新。
BMJ Open. 2019 Nov 11;9(11):e027491. doi: 10.1136/bmjopen-2018-027491.
4
Extending Bayesian back-calculation to estimate age and time specific HIV incidence.扩展贝叶斯反向计算以估计特定年龄和时间的艾滋病毒发病率。
Lifetime Data Anal. 2019 Oct;25(4):757-780. doi: 10.1007/s10985-019-09465-1. Epub 2019 Feb 27.
5
Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.监测英格兰的丙型肝炎流行情况,并使用常规收集的数据评估干预措施的扩展。
J Viral Hepat. 2019 May;26(5):541-551. doi: 10.1111/jvh.13063. Epub 2019 Feb 28.
6
Estimated prevalence of Hepatitis C Virus infection in Canada, 2011.2011年加拿大丙型肝炎病毒感染的估计患病率。
Can Commun Dis Rep. 2014 Dec 18;40(19):429-436. doi: 10.14745/ccdr.v40i19a02.
7
New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England.丙型肝炎病毒(HCV)的新疗法:在英国预防肝病和 HCV 传播的前景
J Viral Hepat. 2016 Aug;23(8):631-43. doi: 10.1111/jvh.12529. Epub 2016 Mar 29.
8
Projections of the current and future disease burden of hepatitis C virus infection in Malaysia.马来西亚丙型肝炎病毒感染当前及未来疾病负担的预测。
PLoS One. 2015 Jun 4;10(6):e0128091. doi: 10.1371/journal.pone.0128091. eCollection 2015.
9
Progress towards a hepatitis C virus vaccine.丙型肝炎病毒疫苗的进展。
Emerg Microbes Infect. 2013 Nov;2(11):e79. doi: 10.1038/emi.2013.79. Epub 2013 Nov 20.
10
Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations.英格兰和威尔士原发性肝癌的发病率与死亡率:变化趋势及种族差异
World J Gastroenterol. 2014 Feb 14;20(6):1544-53. doi: 10.3748/wjg.v20.i6.1544.